Mark Lowdell | CSO
INmuneBio

Mark Lowdell is the co-founder and CSO of INmuneBio Inc & Professor of Cell & Tissue Therapy at University College London. With over 35 years’ experience in cell and gene therapy, his experience includes a variety of adoptive NK cell and T cell therapies, CAR-T cells, dendritic cell vaccines and mesenchymal stromal cells. In 2002 he designed and built the first GMP facility dedicated to ATMP manufacture in the UK and became the first UK QP for ATMPs in 2006. He has held and holds numerous appointments to academic and government advisory boards in the UK and overseas and received the Lifetime Career Achievement Award from the International Society of Cell & Gene Therapy in 2024. He is a scientific advisor to Autolus Ltd, Avectas Ltd, Bio-Recell Ltd, NWBio Therapeutics Inc, Sartorius GmbH, Quell Therapeutics Ltd and ViroCell Biologics Ltd.